Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has completed Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD). Its drug development programs include Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Next Generation Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; and PL-3994, a natriuretic peptide receptor-A agonist that has completed Phase I clinical trial for t...
4B Cedar Brook Drive
Cranbury, NJ 08512
Founded in 1986
Palatin Technologies Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2014
Feb 13 15
Palatin Technologies Inc. announced unaudited consolidated earnings results for the second quarter and six months ended December 31, 2014. For the quarter, the company reported contract revenue of $8,019,415. Income from operations was $2,322,638 against loss of $3,610,438 a year ago. Income before income taxes was $2,245,280 against loss of $3,606,461 a year ago. Net income was $2,776,788 or $0.03 per diluted share against loss of $3,606,461 or $0.03 per diluted share a year ago. The increase in net income for the quarter ended December 31, 2014 compared to the same period last fiscal year was mainly attributable to the recognition of approximately $8.0 million in contract revenue pursuant to its agreement with Gedeon Richter.
For the six months period, the company reported contract revenue of $12,951,730. Income from operations was $3,216,526 against loss of $8,103,088 a year ago. Income before income taxes was $3,039,954 against loss of $8,095,643 a year ago. Net income was $3,571,462 or $0.03 per diluted share against loss of $8,095,643 or $0.08 per diluted share a year ago.
Palatin Technologies Inc. Presents at 27th Annual ROTH Conference, Mar-11-2015 10:30 AM
Feb 13 15
Palatin Technologies Inc. Presents at 27th Annual ROTH Conference, Mar-11-2015 10:30 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Carl Spana, Co-Founder, Chief Executive Officer, President and Director.
Palatin Technologies Inc. to Report Q2, 2015 Results on Feb 13, 2015
Feb 9 15
Palatin Technologies Inc. announced that they will report Q2, 2015 results at 11:00 AM, US Eastern Standard Time on Feb 13, 2015